Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051102 | 0.89 | MAOB (0.50) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL8051104 | 0.89 | MAOB (0.50) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL14970280 | 0.89 | FDPS (0.48) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL16218974 | 0.84 | MAOB (0.41) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL14970269 | 0.81 | GABRA1 (0.47) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL6852962 | 0.80 | CA12 (0.54) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL11347696 | 0.79 | CA12 (0.44) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL11353238 | 0.76 | L3MBTL1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11353236 | 0.76 | L3MBTL1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14970281 | 0.76 | CCNC (0.47) | ESR1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505733-B2 | Single step enantioselective process for the preparation of 3-substituted chiral phthalides | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-11-29 | — | — | US | disclosed |
| US-20150299154-A1 | SINGLE STEP ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CHIRAL PHTHALIDES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-10-22 | — | — | US | disclosed |
| US-9073887-B2 | Single step enantioselective process for the preparation of 3-substituted chiral phthalides | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-07-07 | — | — | US | disclosed |
| US-20140330027-A1 | SINGLE STEP ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CHIRAL PHTHALIDES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330027-A1 | SINGLE STEP ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CHIRAL PHTHALIDES | PPOX, NFE2L2, CBR1 | ESR1 516/4885CA12 1703/4885CA1 2564/4885 |
| US-20150299154-A1 | SINGLE STEP ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CHIRAL PHTHALIDES | PPOX, NFE2L2, CBR1 | ESR1 516/4885CA12 1703/4885CA1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.